Press release
Deadline on October 18th coming up in Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR)
A Deadline is coming up on October 18, 2019 in the lawsuit for certain investors in Nektar Therapeutics (NASDAQ: NKTR).
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and there are strict and short deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Nektar Therapeutics (NASDAQ: NKTR) common shares between February 15, 2019 and August 8, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 15, 2019 and August 8, 2019, the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on October 18th coming up in Lawsuit filed for Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) here
News-ID: 1846432 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for NKTR
Treg Cell-Based Therapies Clinical Trials Analysis 2025: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's "Treg Cell-Based Therapies Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Treg cell-based therapies market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Treg cell-based therapies drugs, the Treg cell-based therapies pipeline analysis…
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunot …
The Treg cell-based therapy landscape is rapidly evolving, with pioneers like Orca Bio, Quell Therapeutics, Nektar Therapeutics, and Abata Therapeutics leading the charge in developing next-generation treatments. These innovative programs are leveraging the unique immunoregulatory power of regulatory T cells to restore immune tolerance, offering promising new strategies for treating autoimmune diseases, chronic inflammation, and transplant rejection. As research progresses, Treg therapies are poised to redefine how we manage immune-related…
Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Inn …
With groundbreaking advancements from industry leaders, the Natural Killer NK Cell Lymphoma pipeline continues to grow, redefining treatment strategies and improving patient outcomes.
DelveInsight's "Natural Killer NK Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Natural Killer NK Cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical…
B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Compan …
DelveInsight's, "B-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the B-Cell Lymphomas…
NK Cell Therapy Market 2020 - 2026 :Nektar Therapeutics, Innate Pharma SA, Affim …
The Global NK Cell Therapy Market Research Report Forecast 2020 - 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope and application…
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: …
An investigation was annpounced concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.
Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over…
